Literature DB >> 11796433

Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Maria T Britto1, Uma R Kotagal, Richard W Hornung, Harry D Atherton, Joel Tsevat, Robert W Wilmott.   

Abstract

OBJECTIVE: To compare the health-related quality of life (HRQOL) of people with cystic fibrosis (CF) to the general population, and to determine the relationship between HRQOL and clinical and demographic factors.
DESIGN: Cross-sectional analysis of observational cohort.
SETTING: Outpatient clinics of a Midwestern CF center.
SUBJECTS: One hundred sixty-two subjects with CF aged 5 to 45 years. MAIN OUTCOME MEASURES: Physical and psychosocial summary scores and individual scale scores for the Child Health Questionnaire and Short Form-36.
RESULTS: Compared with the general population, people with CF reported similar scores for most psychosocial measures, but lower scores for most physical measures, with the lowest scores on the general health perceptions scale. In multivariable analyses, pulmonary exacerbations in the past 6 months were strongly associated with the physical (p = 0.001) and psychosocial (p = 0.0003) scores. The physical score fell, on average, 6 points per exacerbation and the psychosocial score fell 3 points. Lung function, nutrition, 6-min walk distance, age, gender, and insurance status were not significantly associated with HRQOL in this study population. Those who declined to participate had significantly lower FEV(1) percent predicted and nutritional indexes. Our findings may not be generalizable to the entire CF population.
CONCLUSION: Recent pulmonary exacerbations have a profound negative impact on HRQOL that is not explained by differences in lung function, nutritional status, or demographic factors.

Entities:  

Mesh:

Year:  2002        PMID: 11796433     DOI: 10.1378/chest.121.1.64

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  90 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

Review 2.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

3.  Changes in cystic fibrosis airway microbiota at pulmonary exacerbation.

Authors:  Lisa A Carmody; Jiangchao Zhao; Patrick D Schloss; Joseph F Petrosino; Susan Murray; Vincent B Young; Jun Z Li; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2013-06

4.  The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

Authors:  Catherine Norrish; Mark Norrish; Uwe Fass; Majid Al-Salmani; Ganji Shiva Lingam; Fiona Clark; Hebal Kallesh
Journal:  Oman Med J       Date:  2015-01

5.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

6.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

Review 7.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

8.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

10.  Longitudinal trends in health-related quality of life in adults with cystic fibrosis.

Authors:  Edward J Dill; Ree Dawson; Deborah E Sellers; Walter M Robinson; Gregory S Sawicki
Journal:  Chest       Date:  2013-09       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.